DRD2 O
co-expression O
network O
and O
a O
related O
polygenic O
index O
predict O
imaging O
, O
behavioral O
and O
clinical O
phenotypes O
linked O
to O
schizophrenia O
Genetic O
risk O
for O
schizophrenia O
( O
SCZ O
) O
is O
determined O
by O
many O
genetic O
loci O
whose O
compound O
biological O
effects O
are O
difficult O
to O
determine O
. O

We O
hypothesized O
that O
co-expression O
pathways O
of O
SCZ O
risk O
genes O
are O
associated O
with O
system-level O
brain O
function O
and O
clinical O
phenotypes O
of O
SCZ O
. O

We O
examined O
genetic O
variants O
related O
to O
the O
dopamine O
D2 O
receptor O
gene O
DRD2 O
co-expression O
pathway O
and O
associated O
them O
with O
working O
memory O
( O
WM O
) O
behavior O
, O
the O
related O
brain O
activity O
and O
treatment O
response O
. O

Using O
two O
independent O
post-mortem O
prefrontal O
messenger O
RNA O
( O
mRNA O
) O
data O
sets O
( O
total O
N=249 O
) O
, O
we O
identified O
a O
DRD2 O
co-expression O
pathway O
enriched O
for O
SCZ O
risk O
genes O
. O

Next O
, O
we O
identified O
non-coding O
single-nucleotide O
polymorphisms O
( O
SNPs O
) O
associated O
with O
co-expression O
of O
this O
pathway O
. O

These O
SNPs O
were O
associated O
with O
regulatory O
genetic O
loci O
in O
the O
dorsolateral O
prefrontal O
cortex O
( O
P O
< O
0.05 O
) O
. O

We O
summarized O
their O
compound O
effect O
on O
co-expression O
into O
a O
Polygenic O
Co-expression O
Index O
( O
PCI O
) O
, O
which O
predicted O
DRD2 O
pathway O
co-expression O
in O
both O
mRNA O
data O
sets O
( O
all O
P O
< O
0.05 O
) O
. O

We O
associated O
the O
PCI O
with O
brain O
activity O
during O
WM O
performance O
in O
two O
independent O
samples O
of O
healthy O
individuals O
( O
total O
N=368 O
) O
and O
29 O
patients O
with O
SCZ O
who O
performed O
the O
n-back O
task O
. O

Greater O
predicted O
DRD2 O
pathway O
prefrontal O
co-expression O
was O
associated O
with O
greater O
prefrontal O
activity O
and O
longer O
WM O
reaction O
times O
( O
all O
corrected O
P O
< O
0.05 O
) O
, O
thus O
indicating O
inefficient O
WM O
processing O
. O

Blind O
prediction O
of O
treatment O
response O
to O
antipsychotics O
in O
two O
independent O
samples O
of O
patients O
with O
SCZ O
suggested O
better O
clinical O
course O
of O
patientswith O
greater O
PCI O
( O
total O
N=87 O
; O
P O
< O
0.05 O
) O
. O

The O
findings O
on O
this O
DRD2 O
co-expression O
pathway O
are O
a O
proof O
of O
concept O
that O
gene O
co-expression O
can O
parse O
SCZ O
risk O
genes O
into O
biological O
pathways O
associated O
with O
intermediate O
phenotypes O
as O
well O
as O
with O
clinically O
meaningful O
information O
. O

Materials O
and O
methods O
Participants O
Table O
1 O
summarizes O
the O
demographic O
data O
of O
the O
subjects O
included O
in O
all O
experiments O
. O

After O
receiving O
a O
complete O
description O
of O
the O
study O
, O
all O
participants O
in O
the O
clinical O
and O
the O
imaging O
studies O
provided O
written O
informed O
consent O
following O
the O
guidelines O
of O
the O
Declaration O
of O
Helsinki O
. O

Protocols O
and O
procedures O
were O
approved O
by O
the O
ethics O
committee O
of O
the O
University O
of O
Bari O
and O
by O
the O
institutional O
review O
board O
of O
the O
National O
Institute O
of O
Health O
, O
Bethesda O
, O
MD O
, O
USA O
. O

Network O
identification O
We O
used O
the O
publicly O
available O
Braincloud O
data O
set O
( O
http O
: O
//braincloud.jhmi.edu/ O
) O
for O
a O
genome-wide O
Weighted O
Genes O
Co-expression O
Network O
Analysis O
. O

The O
sample O
included O
199 O
observations O
( O
demographics O
in O
Table O
1 O
) O
. O

We O
preprocessed O
the O
gene O
expression O
matrix O
to O
factor O
out O
confounding O
variables O
, O
including O
demographics O
. O

The O
first O
principal O
component O
of O
the O
DRD2 O
gene O
set O
( O
module O
eigengene O
, O
ME O
) O
served O
to O
track O
the O
simultaneous O
variation O
of O
the O
whole O
gene O
set O
. O

We O
correlated O
this O
co-expression O
measure O
with O
DRD2 O
expression O
levels O
. O

To O
investigate O
the O
biological O
functions O
that O
may O
be O
subserved O
by O
this O
ensemble O
of O
co-expressed O
genes O
, O
we O
computed O
gene O
ontology O
enrichment O
analysis O
using O
AmiGO2 O
( O
http O
: O
//amigo.geneontology.org/amigo/landing O
) O
. O

Finally O
, O
we O
assessed O
enrichment O
of O
the O
gene O
set O
for O
the O
loci O
associated O
with O
SCZ O
risk O
by O
the O
Psychiatric O
Genomic O
Consortium O
( O
PGC O
with O
a O
hypergeometric O
test O
( O
SI O
Materials O
and O
Methods O
) O
. O

SNP O
association O
study O
We O
performed O
a O
gene O
set-wide O
association O
study O
of O
SNPs O
with O
the O
ME O
. O

The O
sample O
size O
of O
our O
post-mortem O
data O
set O
is O
probably O
small O
for O
a O
genetic O
association O
study O
, O
and O
co-expression O
is O
most O
likely O
a O
phenotypic O
trait O
with O
complex O
heritability O
, O
much O
like O
SCZ O
. O

Power O
calculations O
in O
genetic O
association O
studies O
have O
been O
shown O
to O
depend O
on O
many O
factors O
, O
including O
heritability O
of O
the O
trait O
, O
the O
proportion O
of O
variance O
explained O
by O
the O
genotyped O
SNPs O
, O
the O
total O
number O
of O
SNPs O
, O
the O
proportion O
of O
SNPs O
with O
no O
effect O
on O
the O
trait O
, O
the O
total O
sample O
size O
and O
the O
P-value O
threshold O
for O
SNP O
selection O
. O

The O
heritability O
of O
expression O
quantitative O
trait O
loci O
( O
eQTLs O
) O
is O
extremely O
variable O
and O
appears O
to O
be O
comparable O
between O
cis- O
and O
trans-eQTLs O
( O
co-eQTLs O
fall O
in O
the O
latter O
category O
) O
. O

Nevertheless O
, O
there O
is O
evidence O
of O
high O
replicability O
of O
eQTLs O
both O
with O
stringent O
and O
more O
lenient O
thresholds O
of O
significance O
. O

These O
findings O
suggest O
that O
, O
beside O
statistical O
significance O
, O
genetic O
signals O
in O
the O
study O
of O
gene O
expression O
may O
be O
found O
beyond O
the O
threshold O
for O
corrected O
or O
nominal O
significance O
, O
as O
is O
also O
the O
case O
of O
complex O
clinical O
traits O
. O

Based O
on O
these O
considerations O
, O
we O
first O
tested O
for O
co-eQTLs O
that O
would O
survive O
stringent O
Bonferroni O
correction O
; O
then O
, O
we O
employed O
more O
permissive O
statistics O
for O
our O
association O
to O
minimize O
false-negative O
findings O
and O
performed O
internal O
cross-validations O
and O
independent O
replication O
to O
minimize O
type O
I O
errors O
. O

Through O
this O
procedure O
, O
we O
aimed O
at O
identifying O
an O
ensemble O
of O
SNPs O
that O
, O
together O
, O
predict O
co-expression O
. O

We O
used O
eight O
SNPs O
associated O
with O
the O
first O
principal O
component O
of O
gene O
set O
co-expression O
with O
P O
< O
0.005 O
to O
compute O
the O
PCI O
. O

As O
a O
common O
method O
to O
select O
SNPs O
for O
subsequent O
inclusion O
in O
polygenic O
scores O
consists O
in O
increasing O
the O
number O
of O
SNPs O
until O
the O
proportion O
of O
variance O
plateaus O
, O
we O
also O
tested O
whether O
such O
an O
approach O
selected O
the O
same O
set O
of O
eight O
SNPs O
with O
P O
< O
0.005 O
( O
SI O
Materials O
and O
Methods O
) O
. O

We O
interrogated O
Haploreg O
v4.1 O
( O
http O
: O
//archive.broadinstitute.org/mammals/haploreg/haploreg.php O
) O
to O
gain O
information O
on O
the O
possible O
regulatory O
functions O
of O
these O
SNPs O
. O

Then O
, O
we O
computed O
the O
PCI O
by O
assigning O
a O
weight O
to O
each O
genotype O
of O
each O
SNP O
based O
on O
the O
expression O
profile O
within O
different O
genotypic O
groups O
. O

The O
greater O
the O
PCI O
, O
the O
greater O
is O
the O
messenger O
RNA O
expression O
level O
of O
that O
individual O
. O

We O
cross-validated O
the O
PCI O
and O
assessed O
ethnicity O
and O
population O
stratification O
effects O
, O
as O
well O
as O
age O
effects O
( O
SI O
Materials O
and O
Methods O
) O
. O

We O
used O
the O
publicly O
available O
BrainEAC O
data O
set O
to O
replicate O
the O
association O
of O
the O
PCI O
with O
D2L O
co-expression O
in O
the O
frontal O
cortex O
. O

From O
this O
data O
set O
, O
we O
selected O
the O
probes O
of O
all O
genes O
included O
in O
the O
D2L O
co-expression O
pathway O
and O
preprocessed O
the O
data O
as O
above O
reported O
. O

The O
sample O
included O
50 O
Caucasian O
participants O
. O

We O
computed O
the O
PCI O
of O
each O
individual O
and O
associated O
it O
with O
the O
ME O
using O
Pearson O
’ O
s O
correlation O
. O

Imaging O
study O
We O
recruited O
124 O
healthy O
unrelated O
Caucasian O
adults O
from O
the O
region O
of O
Apulia O
, O
Italy O
( O
demographics O
in O
Table O
1 O
) O
, O
for O
a O
functional O
magnetic O
resonance O
imaging O
( O
fMRI O
) O
experiment O
and O
genotyped O
them O
for O
the O
SNPs O
included O
in O
the O
PCI O
. O

We O
used O
the O
n-back O
task O
to O
probe O
WM O
. O

Stimuli O
consisted O
of O
numbers O
( O
1–4 O
) O
shown O
in O
random O
sequence O
and O
displayed O
at O
the O
points O
of O
a O
diamond-shaped O
box O
. O

There O
was O
a O
non-memory-guided O
control O
condition O
( O
0-back O
) O
that O
required O
subjects O
to O
identify O
the O
stimulus O
currently O
seen O
. O

As O
memory O
load O
increased O
, O
the O
task O
required O
the O
recollection O
of O
a O
stimulus O
seen O
one O
( O
1-back O
) O
or O
two O
( O
2-back O
) O
stimuli O
before O
, O
while O
keeping O
on O
encoding O
incoming O
stimuli O
( O
SI O
Materials O
and O
Methods O
) O
. O

We O
tested O
the O
association O
of O
the O
PCI O
with O
brain O
activation O
using O
repeated O
measures O
analysis O
of O
covariance O
( O
within-subject O
factor O
: O
LOAD O
( O
1-back O
, O
2-back O
) O
; O
covariates O
: O
age O
, O
gender O
and O
handedness O
; O
whole-brain O
topological O
false O
discovery O
rate-corrected O
α=0.05 O
; O
extent O
threshold=6 O
, O
that O
is O
, O
> O
300 O
mm3 O
) O
. O

We O
recruited O
a O
second O
fMRI O
sample O
of O
244 O
Caucasian O
healthy O
volunteers O
as O
part O
of O
the O
NIMH O
Clinical O
Brain O
Disorders O
Branch O
‘ O
Sibling O
Study O
’ O
( O
Table O
1 O
) O
. O

These O
participants O
performed O
the O
same O
2-back O
fMRI O
task O
described O
above O
and O
were O
genome-wide O
genotyped O
( O
SI O
Materials O
and O
Methods O
) O
. O

The O
effect O
of O
the O
PCI O
on O
BOLD O
response O
was O
tested O
using O
robust O
linear O
models O
with O
age O
, O
gender O
and O
handedness O
as O
covariates O
of O
no O
interest O
. O

We O
performed O
one-tailed O
t-tests O
using O
as O
regions O
of O
interest O
the O
clusters O
associated O
with O
the O
PCI O
in O
the O
first O
healthy O
sample O
. O

We O
used O
MarsBar O
( O
http O
: O
//marsbar.sourceforge.net/ O
) O
to O
extract O
the O
percent O
signal O
change O
and O
corrected O
for O
the O
number O
of O
tests O
( O
false O
discovery O
rate O
) O
. O

For O
the O
fMRI O
study O
on O
the O
clinical O
cohort O
, O
we O
recruited O
29 O
Caucasian O
patients O
with O
SCID O
diagnosis O
of O
SCZ O
from O
the O
region O
of O
Apulia O
, O
Italy O
( O
Table O
1 O
) O
. O

Genotyping O
and O
fMRI O
protocols O
matched O
the O
procedures O
followed O
for O
the O
first O
fMRI O
healthy O
sample O
. O

Behavioral O
analyses O
In O
the O
first O
healthy O
fMRI O
sample O
, O
we O
investigated O
behavioral O
performance O
( O
accuracy O
and O
reaction O
time O
) O
during O
the O
WM O
task O
in O
the O
scanning O
session O
( O
SI O
Materials O
and O
Methods O
) O
. O

We O
analyzed O
accuracy O
, O
that O
is O
, O
percent O
of O
correct O
responses O
, O
and O
reaction O
times O
with O
repeated O
measures O
analysis O
of O
covariance O
( O
within-subject O
factor O
: O
LOAD O
( O
1-back O
, O
2-back O
) O
) O
and O
PCI O
as O
a O
predictor O
. O

As O
we O
were O
testing O
two O
measures O
, O
we O
set O
the O
threshold O
for O
significance O
at O
α=0.025 O
( O
Bonferroni O
correction O
) O
. O

In O
the O
clinical O
fMRI O
sample O
, O
we O
analyzed O
behavioral O
performance O
following O
the O
same O
procedures O
employed O
for O
the O
first O
fMRI O
sample O
. O

Pharmacogenetics O
The O
first O
clinical O
cohort O
in O
the O
pharmacogenetic O
study O
included O
47 O
Caucasian O
patients O
with O
SCZ O
( O
Structured O
Clinical O
Interview O
for O
DSM O
( O
SCID O
) O
diagnosis O
) O
recruited O
from O
the O
region O
of O
Apulia O
, O
Italy O
( O
Table O
1 O
) O
. O

Treatment O
response O
was O
computed O
as O
the O
difference O
in O
the O
total O
Positive O
And O
Negative O
Syndrome O
Scale O
( O
PANSS O
) O
core O
between O
baseline O
and O
treatment O
end O
. O

The O
second O
cohort O
consisted O
of O
40 O
patients O
with O
SCZ O
with O
history O
of O
inadequate O
treatment O
response O
recruited O
at O
the O
Clinical O
Brain O
Disorders O
Branch O
SCZ O
inpatient O
research O
unit O
at O
the O
National O
Institutes O
of O
Health O
Clinical O
Center O
, O
Bethesda O
, O
MD O
, O
USA O
. O

Treatment O
response O
was O
defined O
as O
the O
difference O
between O
symptoms O
severity O
at O
the O
end O
of O
placebo O
treatment O
and O
severity O
at O
the O
end O
of O
drug O
treatment O
. O

The O
clinical O
protocols O
used O
in O
the O
pharmacogenetic O
study O
for O
both O
samples O
have O
been O
described O
in O
detail O
previously O
( O
see O
Supplementary O
Table O
2 O
for O
clinical O
data O
) O
. O

We O
first O
performed O
an O
association O
study O
to O
investigate O
the O
direction O
of O
the O
PCI O
treatment O
response O
relationship O
using O
Spearman O
’ O
s O
Rho O
; O
then O
, O
we O
assessed O
the O
potency O
of O
the O
PCI O
as O
predictor O
of O
treatment O
response O
in O
comparison O
with O
pharmacological O
doses O
and O
off-medication O
symptom O
severity O
using O
Receiver O
Operating O
Characteristic O
curves O
( O
SI O
Materials O
and O
Methods O
) O
. O

